Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain

René Blöcher, Karen M. Wagner, Raghavender R. Gopireddy, Todd R. Harris, Hao Wu, Bogdan Barnych, Sung Hee Hwang, Yang Kevin Xiang, Ewgenij Proschak, Christophe Morisseau, Bruce D. Hammock

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.

Original languageEnglish (US)
Pages (from-to)3541-3550
Number of pages10
JournalJournal of Medicinal Chemistry
Volume61
Issue number8
DOIs
StatePublished - Apr 26 2018

Fingerprint

Phosphodiesterase 4 Inhibitors
Epoxide Hydrolases
Pain
Oral Administration
Analgesics
Lipopolysaccharides
Pharmacokinetics
15-phenyl-beta-methylpentadecanoic acid

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Blöcher, R., Wagner, K. M., Gopireddy, R. R., Harris, T. R., Wu, H., Barnych, B., ... Hammock, B. D. (2018). Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. Journal of Medicinal Chemistry, 61(8), 3541-3550. https://doi.org/10.1021/acs.jmedchem.7b01804

Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. / Blöcher, René; Wagner, Karen M.; Gopireddy, Raghavender R.; Harris, Todd R.; Wu, Hao; Barnych, Bogdan; Hwang, Sung Hee; Xiang, Yang Kevin; Proschak, Ewgenij; Morisseau, Christophe; Hammock, Bruce D.

In: Journal of Medicinal Chemistry, Vol. 61, No. 8, 26.04.2018, p. 3541-3550.

Research output: Contribution to journalArticle

Blöcher, R, Wagner, KM, Gopireddy, RR, Harris, TR, Wu, H, Barnych, B, Hwang, SH, Xiang, YK, Proschak, E, Morisseau, C & Hammock, BD 2018, 'Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain', Journal of Medicinal Chemistry, vol. 61, no. 8, pp. 3541-3550. https://doi.org/10.1021/acs.jmedchem.7b01804
Blöcher, René ; Wagner, Karen M. ; Gopireddy, Raghavender R. ; Harris, Todd R. ; Wu, Hao ; Barnych, Bogdan ; Hwang, Sung Hee ; Xiang, Yang Kevin ; Proschak, Ewgenij ; Morisseau, Christophe ; Hammock, Bruce D. / Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. In: Journal of Medicinal Chemistry. 2018 ; Vol. 61, No. 8. pp. 3541-3550.
@article{e635ed8abcd345a79e617c854970e6ff,
title = "Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain",
abstract = "Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.",
author = "Ren{\'e} Bl{\"o}cher and Wagner, {Karen M.} and Gopireddy, {Raghavender R.} and Harris, {Todd R.} and Hao Wu and Bogdan Barnych and Hwang, {Sung Hee} and Xiang, {Yang Kevin} and Ewgenij Proschak and Christophe Morisseau and Hammock, {Bruce D.}",
year = "2018",
month = "4",
day = "26",
doi = "10.1021/acs.jmedchem.7b01804",
language = "English (US)",
volume = "61",
pages = "3541--3550",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain

AU - Blöcher, René

AU - Wagner, Karen M.

AU - Gopireddy, Raghavender R.

AU - Harris, Todd R.

AU - Wu, Hao

AU - Barnych, Bogdan

AU - Hwang, Sung Hee

AU - Xiang, Yang Kevin

AU - Proschak, Ewgenij

AU - Morisseau, Christophe

AU - Hammock, Bruce D.

PY - 2018/4/26

Y1 - 2018/4/26

N2 - Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.

AB - Inspired by previously discovered enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(trifluoromethyl)benzyl)-1-propionylpiperidine-4-carboxamide (MPPA). In a lipopolysaccharide induced inflammatory pain rat model, MPPA rapidly increased in the blood (Tmax = 30 min; Cmax = 460 nM) after oral administration of 3 mg/kg and reduced inflammatory pain with rapid onset of action correlating with blood levels over a time course of 4 h. Additionally, MPPA does not alter self-motivated exploration of rats with inflammatory pain or the withdrawal latency in control rats.

UR - http://www.scopus.com/inward/record.url?scp=85046004451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046004451&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b01804

DO - 10.1021/acs.jmedchem.7b01804

M3 - Article

C2 - 29614224

AN - SCOPUS:85046004451

VL - 61

SP - 3541

EP - 3550

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 8

ER -